Epilepsy Medicine By Sun Pharmaceutical

more images

NEW DELHI, INDIA (GaeaTimes.com)- The India based Drug making company Sun Pharmaceutical Industries recently declared that it has received the nod of the American Food and Drug Administration to launch one of its drugs in the U.S. market that helps to treat epilepsy. The Sun Pharmaceutical has got the nod of the FDA to market the generic version of the UCB’s Keppra injection. The company will be marketing levetiracetam injection 100 mg/ml that is packaged in 500 mg/ml single use vials.

The Sun Pharmaceutical’s drug is an alternative or a secondary therapy in the treatment of seizures from epilepsy in adults. The injection would be put to use when oral supplements to restrict the seizure is not feasible in some particular cases. The Sun Pharmaceutical is hoping that it will be able to make huge profit in the American market where there has been rise in the demand of the epilepsy treatments. According to reports, the company is hoping that levetiracetam injections will be able to get an annual sale of $85 million in the U.S. market.

There is no doubt about the fact that the levetiracetam injections whose vial package will equal the 100 mg/ml of the UCB’s Keppra injections would be able to provide a steep competition to the sale of the latter in the U.S. market on the ground of the epilepsy medicine. The shares of Sun Pharmaceutical has also seen a rise after the declaration made by the company. The shares of the company after the announcement were trading at Rs 1,706.10 at late afternoon at the Bombay Stock Exchange that was up to 0.35 per cent from its previous day close.